



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Duff *et al.*

SERIAL NUMBER: 09/845,129

EXAMINER: Chakrabarti, Arun K.

FILING DATE: April 27, 2001

ART UNIT: 1634

FOR: DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH AN IL-1 INFLAMMATORY HAPLOTYPE

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

## REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

Interleukin Genetics, Inc., owner of the above-identified application hereby revokes any and all former power of attorney and appoints:



all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicant's attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent application.

Interleukin Genetics, Inc. certifies under 37 C.F.R. § 3.73(b)(ii) that it is the Assignee of the entire right, title and interest in the patent application identified above by virtue of assignment of the parent application 09/345,217, filed June 30, 1999 (now U.S. Pat. No. 6,268,142) recorded on February 3, 2000 at Reel 010349, Frame 0150.


I, the undersigned, am empowered to act on behalf of the Assignee. Acting on behalf of the Assignee, I have reviewed all the documents in the chain of title of the patent application identified above and, to the best of my knowledge and belief, title is in the Assignee identified above.

I, the undersigned, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and

I, the undersigned, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the patent.

Please charge any fee or any fee deficiency occasioned by this document to Deposit Account No. 50-0311, Attorney Reference No. 24299-508CON2 (Customer Number: 30623).

Respectfully submitted,

  
\_\_\_\_\_  
NAME: Philip R. Reilly  
TITLE: CEO

Date: June 11, 2003

TRA 1798763v1